Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Visit 1 Ponderosa CML ZKSJ0083 - Visit 1

- 2021-09-20 - 1 Formulier, 11 Itemgroepen, 191 Data-elementen, 1 Taal

Itemgroepen: Inclusion Criteria, Exclusion Criteria, Informed consent, Demographics, Myeloid Leukemia, Chronic, therapy CML, Patient medical history, medical history, Blood pressure, Laboratory parameters, Treatment

Study part: Visit 1.Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

The effect of intranasal capsaicin challenge model in healthy volunteers - 111611 - Period 2

- 2019-03-13 - 1 Formulier, 12 Itemgroepen, 87 Data-elementen, 2 Talen

Itemgroepen: Administrative data, Investigational Product (Dose), Vital Signs (Dosing), Temperature (Dosing), Hematology (Dosing), Clinical Chemistry, Electrocardiogram, Peak Nasal Inspiratory Flow Rate, Total Symptom Score, Visual Analogue Scale, Nostril Secretions, Pharmacokinetics - Blood

Study ID: 111611 Clinical Study ID: 111611 Study Title: A randomised, double-blind, placebo-controlled study to assess the effect of oral, single dose SB-705498 in a validated intranasal capsaicin challenge model in healthy volunteers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00731250 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: SB-705498, Placebo, Caspaicin Trade Name: N/A Study Indication: Rhinitis

Pharmacokinetics of an oral contraceptive co-administered with Albiglutide in women - 107032 - Period 2 Day 1 + Day 5

- 2018-12-27 - 1 Formulier, 15 Itemgroepen, 80 Data-elementen, 1 Taal

Itemgroepen: Administrative data, Day 1, Vital Signs - Duplicate 1, Vital Signs - Duplicate 2, Study Drug Administration, Hematology Test, Chemistry, UA / UDS / Urine HCG / Urine Chemistry, Pharmacodynamic Blood Collection, Pharmacodynamic Blood Collection 2, Day 5, Vital Signs - Duplicate 1, Vital Signs - Duplicate 2, Study Drug Administration, Study Drug Administration 2

Study ID: 107032 Clinical Study ID: GLP107032 Study Title: An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01077505 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Pharmacokinetics of an oral contraceptive co-administered with Albiglutide in women - 107032 - Period 1 Day 1 (Visit 80)

- 2018-12-21 - 1 Formulier, 9 Itemgroepen, 49 Data-elementen, 1 Taal

Itemgroepen: Administrative data, Admission Criteria, Study Drug Administration, Laboratory Test - Hematology, Laboratory Test - Chemistry, Laboratory Test - UA / UDS / Urine HCG / Urine Chemistry, Vital Signs, Pharmacodynamic Blood Collection, Pharmacodynamic Blood Collection

Study ID: 107032 Clinical Study ID: GLP107032 Study Title: An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01077505 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2